Wolstencroft PW, et al. - In adults with dermatomyositis, researchers assessed disease characteristics that increase hydroxychloroquine-associated skin eruption risk via conducting a retrospective cohort study in the outpatient dermatology clinic at a tertiary academic referral center. Eligibility criteria included all adults with dermatomyositis (age >18 years) who began hydroxychloroquine between July 1, 1990 and September 13, 2016. In a US cohort of patients with dermatomyositis, adverse skin reactions to hydroxychloroquine were fairly common. In dermatomyositis, pathophysiologic differences exist between autoantibody subsets. The presence of anti–SAE-1/2 autoantibodies significantly correlated with a hydroxychloroquine-associated skin eruption and presence of anti–MDA-5 autoantibodies significantly negatively correlated with a hydroxychloroquine-associated skin eruption in exact logistic regressions adjusted for age, race/ethnicity, sex, amyopathic status, anti–Ro52 status, and dermatomyositis-associated cancer.